Myeloproliferative Neoplasms — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Myeloproliferative Neoplasms.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Myeloproliferative Neoplasms and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Rivière E, Guy A, Mansier O, Mediavilla C, et al. Autoimmunity and peginterferon therapy for polycythemia vera Hemasphere, 2026.PMID 42465525
[2]Hu LJ, Yang WY [Progress in the study of polycythemia vera in children] Zhongguo Dang Dai Er Ke Za Zhi, 2026.PMID 42457335
[3]Gašljević G, Dora P, Grčar-Kuzmanov B, Urdih T, et al. ARAF mutated langerhans cell histiocytosis developed on the background of ARAF/JAK2 mutated polycythaemia vera: evidence of branching evolution from the same progenitor cell. A case report and literature review Ann Hematol, 2026.PMID 42448959
[4]Gerds AT, Gotlib J, Abdelmessieh P, Ali H, et al. NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026 J Natl Compr Canc Netw, 2026.PMID 42425157
[5]Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association [Chinese guidelines on the diagnosis and treatment of adult essential thrombocythemia (2026)] Zhonghua Xue Ye Xue Za Zhi, 2026.PMID 42409729
[6]Leiva O, Liu OC, Ferrante M, Katsadouros VP, et al. Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know Semin Hematol, 2026.PMID 42243010
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Myeloproliferative Neoplasms and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Rivière E, Guy A, Mansier O, Mediavilla C, et al. Autoimmunity and peginterferon therapy for polycythemia vera Hemasphere, 2026.PMID 42465525
[2]Hu LJ, Yang WY [Progress in the study of polycythemia vera in children] Zhongguo Dang Dai Er Ke Za Zhi, 2026.PMID 42457335
[3]Gašljević G, Dora P, Grčar-Kuzmanov B, Urdih T, et al. ARAF mutated langerhans cell histiocytosis developed on the background of ARAF/JAK2 mutated polycythaemia vera: evidence of branching evolution from the same progenitor cell. A case report and literature review Ann Hematol, 2026.PMID 42448959
[4]Gerds AT, Gotlib J, Abdelmessieh P, Ali H, et al. NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026 J Natl Compr Canc Netw, 2026.PMID 42425157
[5]Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association [Chinese guidelines on the diagnosis and treatment of adult essential thrombocythemia (2026)] Zhonghua Xue Ye Xue Za Zhi, 2026.PMID 42409729
[6]Leiva O, Liu OC, Ferrante M, Katsadouros VP, et al. Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know Semin Hematol, 2026.PMID 42243010
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922